Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AstraZeneca
Budesonide/formoterol in a single inhaler is more effective than fluticasone alone
June 23rd, 2006
Budesonide/formoterol in a single inhaler is more effective and associated with significantly lower total healthcare costs than a higher microgram dose of fluticasone. According to recent research published in the journal Respiratory Medicine, "In this economic evaluation, conducted alongside a randomized, double-blind clinical trial, economic data were collected from 339 patients with moderate-persistent asthma randomized to receive twice-daily, double-blind treatment with budesonide/formoterol 160/4.5 mcg in a single inhaler (n=166) or fluticasone propionate 250 mcg (n=173) for 12 weeks. The mean number of episode-free days (EFD) per patient was significantly...
Source: Biotech Law Weekly (2006-06-23)
|
